These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16428243)

  • 41. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group.
    J Natl Cancer Inst; 1996 Dec; 88(24):1834-9. PubMed ID: 8961973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fertility preservation in (breast) cancer patients: is it safe?
    Wildiers H; Neven P; Amant F; D'hooghe T; Paridaens R
    J Clin Oncol; 2006 Nov; 24(33):5335-6; author reply 5337-8. PubMed ID: 17114672
    [No Abstract]   [Full Text] [Related]  

  • 44. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant endocrine therapy in breast cancer.
    Beresford MJ; Ravichandran D; Makris A
    Cancer Treat Rev; 2007 Feb; 33(1):48-57. PubMed ID: 17134840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
    J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant tamoxifen: 5 year control of dormant disease?
    Merimsky O; Inbar M; Kovner F; Chaitchik S
    Eur J Cancer; 1996 Jan; 32A(1):174. PubMed ID: 8695228
    [No Abstract]   [Full Text] [Related]  

  • 48. Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
    Langenegger T; Wahl P; Schiesser D; Thürlimann B
    Breast Cancer Res Treat; 2006 Nov; 100(2):177-81. PubMed ID: 16688477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endocrine therapy for hormone treatment-naïve advanced breast cancer.
    Martin M; Lopez-Tarruella S; Gilarranz YJ
    Breast; 2016 Aug; 28():161-6. PubMed ID: 27326977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Chemo/endocrine therapy for breast cancer patients].
    Ikeda T; Masamura S; Matsui A; Hohjoh T; Kawaguchi M; Takayama S; Tokura H; Mitsui Y; Fujiwara K; Kitajima M
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1225-32. PubMed ID: 10945021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing side effects in adjuvant endocrine therapy for breast cancer.
    Condorelli R; Vaz-Luis I
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1101-1112. PubMed ID: 30188738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see--that is the question!
    Bentzen SM; Yarnold JR
    J Clin Oncol; 2005 Sep; 23(25):6266-7; author reply 6267. PubMed ID: 16135499
    [No Abstract]   [Full Text] [Related]  

  • 53. Preoperative endocrine therapy for older women with breast cancer: renewed interest in an old idea.
    Ellis MJ
    Cancer Control; 2000; 7(6):557-62. PubMed ID: 11088064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonadherence in patients with breast cancer receiving oral therapies.
    Moore S
    Clin J Oncol Nurs; 2010 Feb; 14(1):41-7. PubMed ID: 20118025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Importance of long-term follow-up of women receiving adjuvant therapy for breast cancer in the community.
    McCowan C; Dewar JA; Thompson AM
    J Clin Oncol; 2011 Sep; 29(25):3492; author reply 3492; discussion 3492-3. PubMed ID: 21768466
    [No Abstract]   [Full Text] [Related]  

  • 56. Tamoxifen for early breast cancer: better late than never.
    Gray R; Davies C; Perry P
    Ann Oncol; 2000 May; 11(5):505-7. PubMed ID: 10907940
    [No Abstract]   [Full Text] [Related]  

  • 57. The renaissance of endocrine therapy in breast cancer.
    Williams N; Harris LN
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):41-7. PubMed ID: 24346127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The breast cancer prevention trial: should women at risk take tamoxifen?
    McKeon VA
    J Obstet Gynecol Neonatal Nurs; 1999; 28(6 Suppl 1):34-8. PubMed ID: 10608495
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.
    Machin D; Andersen KW
    J Natl Cancer Inst; 1997 May; 89(9):659-60. PubMed ID: 9150193
    [No Abstract]   [Full Text] [Related]  

  • 60. Is bcl-2 useful to select endocrine therapy for breast cancer?
    Yang Q
    Clin Breast Cancer; 2004 Dec; 5(5):370. PubMed ID: 15585075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.